Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68373 | 0.85 | PDE4D (0.42) | PTPN1PDE4DVDRPPARDCALM1 | |
| SCHEMBL5197226 | 0.83 | CCNT1 (0.53) | CCNT1PTGER2GAAPTPRC | |
| SCHEMBL68953 | 0.81 | CCNT1 (0.49) | CCNT1GAA | |
| SCHEMBL3697027 | 0.80 | CCNT1 (0.49) | CCNT1GAA | |
| SCHEMBL3697028 | 0.80 | CCNT1 (0.49) | CCNT1GAA | |
| SCHEMBL68955 | 0.79 | CCNT1 (0.49) | CCNT1PTGER2GAAPTPRC | |
| SCHEMBL68954 | 0.79 | CCNT1 (0.49) | CCNT1PTGER2GAAPTPRC | |
| SCHEMBL6720555 | 0.75 | CCNT1 (0.41) | CCNT1PTGER2 | |
| SCHEMBL5262346 | 0.70 | SIRT2 (0.49) | PTPN1CNR2 | |
| SCHEMBL68359 | 0.70 | HPGD (0.39) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RES & DEV (FR) | 2013-11-14 | — | — | US | disclosed |
| US-8513297-B2 | Biaromatic compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8129416-B2 | Biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-03-06 | — | — | US | disclosed |
| EP-1814871-B1 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-31 | — | — | US | disclosed |
| EP-1814871-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006053791-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | CCNT1 4281/4885PTPN1 888/4885PDE4D 1451/4885 |
| US-20130303549-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | CCNT1 4612/4885PTPN1 707/4885PDE4D 1014/4885 |
| US-20120121527-A1 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARD, PPARA | CCNT1 4612/4885PTPN1 707/4885PDE4D 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.